[{"id":"90cb730b-e951-47bb-90b3-33fbbfea086a","acronym":"KEYNOTE-555","url":"https://clinicaltrials.gov/study/NCT03665597","created_at":"2021-01-18T17:59:10.061Z","updated_at":"2025-02-25T15:17:51.739Z","phase":"Phase 1","brief_title":"Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)","source_id_and_acronym":"NCT03665597 - KEYNOTE-555","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF • TNFRSF9","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC"],"overall_status":"Completed","enrollment":" Enrollment 138","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/04/2023","study_completion_date":" 12/04/2023","last_update_posted":"2025-02-10"},{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2025-02-25T16:07:00.519Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-22"},{"id":"c8f0a2ef-9f1a-4761-9b4a-e741d01eacaa","acronym":"KEYNOTE-A86","url":"https://clinicaltrials.gov/study/NCT04956692","created_at":"2021-07-09T12:57:25.096Z","updated_at":"2024-07-02T16:35:02.674Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","source_id_and_acronym":"NCT04956692 - KEYNOTE-A86","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • MK-3475 SC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 531","initiation":"Initiation: 08/05/2021","start_date":" 08/05/2021","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 10/14/2026","study_completion_date":" 10/14/2026","last_update_posted":"2024-05-17"}]